NCT06861985

Brief Summary

Investigated the effects of high-frequency multi-band harmonic electromagnetic stimulation on ophthalmic and central retinal artery circulation.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
43

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Sep 2023

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 20, 2023

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 20, 2023

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2023

Completed
1.1 years until next milestone

First Submitted

Initial submission to the registry

February 18, 2025

Completed
16 days until next milestone

First Posted

Study publicly available on registry

March 6, 2025

Completed
Last Updated

March 6, 2025

Status Verified

March 1, 2025

Enrollment Period

Same day

First QC Date

February 18, 2025

Last Update Submit

March 2, 2025

Conditions

Outcome Measures

Primary Outcomes (3)

  • Peak Systolic Velocity (PSV)

    peak systolic velocity (PSV) of the ophthalmic artery (OA) were measured using color Doppler ultrasound of the eye arterial blood flow (EPIQ Elite ultrasound system, PHILIPS).

    At the first visit and after 90 minutes usage of device.

  • End Diastolic Velocity (EDV)

    end diastolic velocity (EDV) of the ophthalmic artery (OA) were measured using color Doppler ultrasound of the eye arterial blood flow (EPIQ Elite ultrasound system, PHILIPS).

    At the first visit and after 90 minutes usage of device.

  • Central Retinal Artery (CRA)

    Central Retinal Artery (CRA) were measured using color Doppler ultrasound of the eye arterial blood flow (EPIQ Elite ultrasound system, PHILIPS).

    At the first visit and after 90 minutes usage of device.

Study Arms (2)

experimental group

EXPERIMENTAL

high-frequency multi-band harmonic electromagnetic stimulation device group

Device: BOBY

control group

PLACEBO COMPARATOR

placebo device group

Other: Control

Interventions

BOBYDEVICE

high-frequency multi-band harmonic electromagnetic stimulation device

experimental group
ControlOTHER

placebo group

control group

Eligibility Criteria

Age20 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • to 65 years old

You may not qualify if:

  • hypertension
  • diabetes
  • heart disease
  • eye-related diseases

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National Central University

Hsinchu, Taiwan, 30013, Taiwan

Location

MeSH Terms

Conditions

Retinal Artery Occlusion

Condition Hierarchy (Ancestors)

Retinal DiseasesEye DiseasesArterial Occlusive DiseasesVascular DiseasesCardiovascular Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: This study is a randomized double-blind controlled trial. All participants who meet the inclusion criteria are randomly assigned to either the "high-frequency multi-band harmonic electromagnetic stimulation device group" as the experimental group or the "placebo device group" as the control group.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 18, 2025

First Posted

March 6, 2025

Study Start

September 20, 2023

Primary Completion

September 20, 2023

Study Completion

December 31, 2023

Last Updated

March 6, 2025

Record last verified: 2025-03

Data Sharing

IPD Sharing
Will not share

Locations